Ruxolitinib

From WikiMD.org
Jump to navigation Jump to search

Ruxolitinib

Ruxolitinib (pronounced rooks-oh-LIT-in-ib) is a medication used in the treatment of certain types of cancer and myelofibrosis, a serious bone marrow disorder. It is marketed under the brand names Jakafi and Jakavi.

Etymology

The name Ruxolitinib is derived from its chemical structure. The "Ruxo" part of the name is a reference to its chemical class, while the "itinib" suffix is common in drugs that inhibit specific enzymes.

Usage

Ruxolitinib is a Janus kinase inhibitor, which works by blocking certain enzymes in the body that affect blood cell production. It is used to treat myelofibrosis and polycythemia vera, which are bone marrow disorders that affect your body's ability to produce blood cells. It is also used to treat a certain type of acute graft versus host disease (GVHD) in adults and children who are at least 12 years old.

Side Effects

Common side effects of Ruxolitinib include anemia, thrombocytopenia, bruising, dizziness, and headache. Serious side effects may include infections, cancer, and a decrease in blood cell counts.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski